VivoCAR™ Anti-CD19 (4G7) h(CD28-41BB-CD3z) CAR saRNA (XS-0326-XU3)

Name: VivoCAR™ Anti-CD19 (4G7) h(CD28-41BB-CD3z) CAR saRNA
SKU: XS-0326-XU3
Rating: 5 (1 reviews)

Online Inquiry Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

VivoCAR™ Anti-CD19 (4G7) h(CD28-41BB-CD3z) CAR saRNA leverages the potent 4G7 clone, a highly characterized binder often selected for its favorable safety profile and low tonic signaling. In the context of in vivo CAR-T engineering, the 4G7 clone is essential for preventing premature T-cell exhaustion-a common hurdle when CARs are expressed natively in the body. The saRNA platform enhances this by providing steady-state protein production that, when paired with the 4G7 clone's balanced affinity, results in a controlled yet vigorous anti-tumor response. This product is specifically designed for in vivo applications requiring a high safety margin and persistent surveillance of the B-cell compartment.

Add to Cart

CAR Information

Target
CD19

Target Species
Human

Antibody Clone
4G7

scFv Host Species
Mouse

Receptor Construction
CD28-41BB-CD3z

Generation
Third

Description of Signaling Cassetes
The third-generation CD28-41BB-CD3ζ architecture employs a sequential costimulatory strategy, where the CD28 module drives rapid initial activation and metabolic reprogramming, while the 4-1BB component sustains long-term cellular viability and mitigates exhaustion. This tandem design, anchored by the CD3ζ signaling chain, synergistically amplifies downstream signal transduction, resulting in a balanced T-cell phenotype with robust effector capacity and prolonged durability. The integrated signaling cascade thus optimizes both kinetic expansion and persistence, enhancing antitumor efficacy.

CAR saRNA Properties

Structure
Linear

Cap
Cap 1

PolyA
Segmented PolyA

Product Type
CAR IVT saRNA

Concentration
Lot specific

Buffer
1 mM Sodium Citrate, pH 6.4 (or specialized RNA storage buffer, RNase-free).

Storage
Aliquot and store at -80°C. Avoid freeze/thaw cycles.

Handling
Thaw and work with RNA on ice. Upon first use, pulse spin before opening and aliquot into single use portions. DO NOT vortex. Use only certified RNase-free reagents and consumables with proper RNase-free technique. Use of barrier tips is recommended. Avoid freeze/thaw cycles. DO NOT mix with media containing serum unless first complexed with a stabilizing transfection reagent.

saRNA Quality Control

IVT Vector Sequencing
Pass

IVT Vector Enzyme Digestion
Pass

Purity OD260/280
Pass

RNA Length and Integrity Assessment (Determined by Denaturing Agarose Gel Electrophoresis)
Pass

RNA Sequence Assessment
Pass

Endotoxin (<10 EU/mg)
Pass

In Vitro Transfection and Expression (Optional)
Pass

Target Information

Full Name
B-lymphocyte antigen CD19

Alternative Names
B-lymphocyte antigen CD19; B4; CVID3

Introduction
CD19 is a critical B-cell surface adapter protein and a member of the immunoglobulin superfamily. It acts as a dominant co-receptor for B-cell antigen receptor (BCR) signaling and is expressed throughout B-cell development until terminal differentiation into plasma cells, making it a premier target for CAR-based therapies.

Targeting Diseases
Chronic lymphocytic leukemia (CLL)

UniProt ID
P15391

Gene ID
930

Related Resources

Overview of CD19-Targeted CAR Cell Therapies

Case Studies

Customer Reviews and Q&As

There are currently no customer reviews or questions for VivoCAR™ Anti-CD19 (4G7) h(CD28-41BB-CD3z) CAR saRNA (XS-0326-XU3). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.